Gilead Sciences (GILD) Stock is the 'Chart of the Day'

Gilead Sciences (GILD) stock is the 'Chart of the Day.'
By Amanda Albright ,

NEW YORK (TheStreet) -- Gilead Sciences  (GILD) - Get Report stock is down by 0.65% to $101.90 in early afternoon trading on Monday.

The bio-pharmaceutical company develops and commercialized medicines, with a focus on HIV, liver diseases and cardiovascular and respiratory conditions. 

Last week, the company announced that the U.S. Food and Drug Administration approved its treatment for the liver infection Hepatitis C. 

"Harvoni - the first and only single-tablet regimen for the treatment of HCV - continues to demonstrate high cure rates and a tolerable side effect profile across a range of patient populations, including those who have historically been considered among the most difficult to cure," Chief Scientific Officer Norbert Bischofberger said in a statement. 

TheStreet's Chris Versace and Bob Lang of Trifecta Stocks have identified Gilead Sciences as the "Chart of the Day." Here is what Versace and Lang had to say about the company:

Gilead Sciences certainly looked ready to take its game to another level. The breakout seen in late October was on strong turnover, which shows institutional support. Yet, the stock fell back into a modest range and distribution shortly thereafter, and now we see three big red candles.

This brings the stock back to its lower Bollinger band, oversold but not a place to buy. The moving average convergence divergence (MACD) has started to roll over and the uptrend line has been violated. The momentum indicators are not yet oversold and show more downside to go. For upside, there is clear resistance at $110.

- Chris Versace and Bob Lang "Chart of the Day: GILD" originally published on 11/16/15 on Trifecta Stocks.

Want more like this from Chris Versace and Bob Lang BEFORE your stock moves? Learn more about Trifecta Stocks now!

Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:

We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

You can view the full analysis from the report here: GILD

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.

Loading ...